Perspectives on the Management of Chronic GVHD
EP. 1: Graft versus Host Disease Background
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.
EP. 2: Overview of GVHD Risk Factors
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.
EP. 3: Current GVHD Prophylaxis Strategies
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.
EP. 4: Signs and Symptoms of Acute and Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.
EP. 5: Statistics on the Incidence of Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Dr Chen presents statistics on the incidence of chronic graft versus host disease.
EP. 6: Identification of Patients at High Risk for GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS The panelists share their insights on the identification of patients at high risk for GVHD.
EP. 7: Assessment of Chronic GVHD Symptoms
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.
EP. 8: The NIH Clinical Scoring of Organ Systems
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.
EP. 9: The Chronic GVHD Treatment Paradigm
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.
EP. 10: Patient Case: A 48-Year-Old Man with Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.
EP. 11: Treatment Goals for a Patient With Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS The group discusses treatment goals and patient education for chronic GVHD.
EP. 12: Steroid-Refractory Chronic GVHD Background
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.
EP. 13: Therapy Options for Steroid-Refractory Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.
EP. 14: Ibrutinib as Second-Line Therapy for Steroid-Refractory Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.
EP. 15: The iNTEGRATE Trial: Ibrutinib With Prednisone as First-Line Therapy for cGVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.
EP. 16: The REACH3 Clinical Trial of Ruxolitinib in Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.
EP. 17: Clinical Experience with Ruxolitinib for cGVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.
EP. 18: The ROCKstar Study of Belumosudil in cGVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.
EP. 19: Real-World Experience with Belumosudil
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Clinical experiences with belusmosudil are shared among the panel.
EP. 20: Summary of Axatilimab for cGVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.
EP. 21: Therapy Selection for Patients with Chronic GVHD
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS The panel debates the various treatment options and comments on when they prefer each one.
EP. 22: Discussion of Long-Term Effects of GVHD Therapy
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.
EP. 23: Future Directions in Graft Versus Host Disease
ByYi-Bin Chen, MD,Corey S. Cutler, MD, MPH, FRCPC,Colleen Danielson, NP,Catherine J. Lee, MD, MS Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.